Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

China Pharma second-quarter revenue increases 22% to $16.6 million

China Pharma Holdings, Inc., a leading fully-integrated specialty pharmaceuticals company in China, today announced financial results for the second quarter ended June 30, 2010.

10 Aug 2010

FDA accepts Salix's XIFAXAN550 sNDA for Priority Review

Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Company's efficacy supplement to the New Drug Application (NDA) for XIFAXAN® (rifaximin) 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome (Non-C IBS) and IBS-related bloating.

9 Aug 2010

Lexicon Pharmaceuticals updates key progress in clinical pipeline

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated the progress of its drug development programs and reported financial results for the three and six months ended June 30, 2010.

9 Aug 2010

Ironwood provides investor update for second-quarter 2010

Ironwood Pharmaceuticals, Inc. today provided an update on its business activities for the second quarter of 2010.

7 Aug 2010

Sucampo Pharmaceuticals second-quarter 2010 total revenue declines to $13.8 million

Sucampo Pharmaceuticals, Inc. today reported its consolidated financial results for the quarter and six months ended June 30, 2010.

7 Aug 2010

Osiris Therapeutics reports second-quarter net income of $1.7M against loss last year

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products to treat medical conditions in the inflammatory, autoimmune, cardiovascular and orthopedic areas, announced today its results for the second quarter of fiscal 2010.

7 Aug 2010

Clinical trials in Asia, Africa confirm safety, effectiveness of rotavirus vaccine

Two studies published online Thursday in the Lancet show that the rotavirus vaccine is safe and effective at preventing much of the gastrointestinal illness in developing countries, where rotavirus kills more than 400,000 children under age 5 annually, Reuters reports. Based on the findings in Asia and Africa, the studies' authors "urged the governments of developing nations to make the vaccines a priority," the news service writes.

7 Aug 2010

Scientific findings reveal combination antibiotic therapy effective for ulcerative colitis

The link between Hormone Replacement Therapy and reduced risk of distal large bowel cancer in women; a promising combination antibiotic therapy for ulcerative colitis patients; and the high-rate of alcoholic liver disease mortality, are among the scientific findings featured in the August issue of The American Journal of Gastroenterology.

6 Aug 2010

Studies show biological agents play important role in maintaining remission in Crohn's disease

Biological agents may play an important role in maintaining remission in Crohn's disease, according to two new studies in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association Institute.

6 Aug 2010

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Repligen Corporation today reported results for the first quarter of fiscal year 2011, ended June 30, 2010. Total revenue for the first quarter was $7,010,000 compared to total revenue of $5,061,000 for the first quarter of fiscal year 2010, an increase of $1,949,000 or 39%. Bioprocessing product revenue for the first quarter was $4,269,000 compared to $2,473,000 for the first quarter of fiscal 2010, an increase of $1,796,000 or 73%.

5 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

Shire proposes acquisition of Movetis for fully diluted equity purchase price of EUR428 million

Shire plc, the global specialty biopharmaceutical company, announces that a Luxembourg incorporated wholly-owned subsidiary of Shire plc will launch a voluntary public takeover offer for all the shares in Movetis NV, the Belgium-based European specialty gastrointestinal (GI) company. Movetis is listed on Euronext and focuses on discovering, developing and commercializing innovative treatments for GI conditions with a high unmet medical need.

5 Aug 2010

New trend in management of post-liver transplantation biliary strictures

Endoscopic intervention has emerged to become the first line treatment for benign biliary strictures following liver transplantation. The current endoscopic approach involves repetitive dilatation of the stricture and placement of multiple large-diameter parallel plastic stents with frequent stent exchange to prevent biliary infection.

3 Aug 2010

PHD1 useful for pharmacologic inhibition in IBD: Research

Research into inflammatory bowel disease (IBD) led by UCD Conway Institute scientists with national and international collaborators has identified a key regulator involved in maintaining the functional integrity of the gut lining. The findings, published recently in the scientific journal, Gastroenterology, provide information that may be important in developing a new therapeutic approach to the treatment of the disease.

3 Aug 2010

Study explores role of genetic influence on ulcerative colitis

Adults diagnosed with ulcerative colitis after age 50 are more likely to achieve remission from their symptoms than patients diagnosed at younger ages, even when those patients receive similar treatments, according to research at Washington University School of Medicine in St. Louis.

3 Aug 2010

Researchers discover manipulation of microRNA-29a shows potential of novel IBS treatment

A possible cause of irritable bowel syndrome has been traced to a small piece of RNA that blocks a substance protecting the colon membrane, leading to hostile conditions that can produce diarrhea, bloating and chronic abdominal pain.New research shows that this RNA segment sends signals that stop the activity of the gene that produces glutamine, an amino acid. Previous research has linked a shortage of glutamine in the gut with the seepage of toxins and bacteria through the intestinal wall, irritating nerves and creating disease symptoms.

3 Aug 2010

Repligen receives three additional grants to develop HDAC inhibitors for neurodegenerative diseases

Repligen Corporation today announced that the Company has received three additional grants to support its research program to develop HDAC inhibitors for neurodegenerative diseases. Repligen has received $436,000 in research funding to support the ongoing development of histone deacetylase inhibitors for Friedreich's ataxia.

2 Aug 2010

Lexicon acquires equity shares of Symphony Icon Holdings

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today announced that it has exercised a restructured purchase option under its drug development financing collaboration with Symphony Icon Holdings LLC and acquired all the equity of Symphony Icon, Inc., thereby reacquiring all rights to LX1031, LX1032, LX1033 and the other drug programs subject to the collaboration.

2 Aug 2010

Warner Chilcott announces $2.25 billion of new debt to fund special dividend

Warner Chilcott plc today announced a recapitalization pursuant to which it intends to incur, subject to market and other conditions, $2.25 billion of new debt to fund a special dividend to Warner Chilcott's ordinary shareholders of $8.50 per share, or approximately $2.15 billion in the aggregate. The new debt is expected to be comprised of a combination of senior secured term loans and additional unsecured debt.

31 Jul 2010

VBDS secondary to nevirapine use in HIV-positive, pregnant female: Report

Vanishing bile duct syndrome refers to a group of disorders characterized by destruction and disappearance of intrahepatic (inside the liver) bile ducts. Multiple causes have been identified including infections, malignancies, autoimmune conditions and adverse effects of medications. The usual course of this condition is variable and many patients with VBDS respond to treatment of the underlying condition and/ or removal of the offending agent. However, others progress to cirrhosis and end stage liver disease requiring liver transplantation.

31 Jul 2010

Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

China Pharma second-quarter revenue increases 22% to $16.6 million

FDA accepts Salix's XIFAXAN550 sNDA for Priority Review

Lexicon Pharmaceuticals updates key progress in clinical pipeline

Ironwood provides investor update for second-quarter 2010

Sucampo Pharmaceuticals second-quarter 2010 total revenue declines to $13.8 million

Osiris Therapeutics reports second-quarter net income of $1.7M against loss last year

Clinical trials in Asia, Africa confirm safety, effectiveness of rotavirus vaccine

Scientific findings reveal combination antibiotic therapy effective for ulcerative colitis

Studies show biological agents play important role in maintaining remission in Crohn's disease

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Shire proposes acquisition of Movetis for fully diluted equity purchase price of EUR428 million

New trend in management of post-liver transplantation biliary strictures

PHD1 useful for pharmacologic inhibition in IBD: Research

Study explores role of genetic influence on ulcerative colitis

Researchers discover manipulation of microRNA-29a shows potential of novel IBS treatment

Repligen receives three additional grants to develop HDAC inhibitors for neurodegenerative diseases

Lexicon acquires equity shares of Symphony Icon Holdings

Warner Chilcott announces $2.25 billion of new debt to fund special dividend

VBDS secondary to nevirapine use in HIV-positive, pregnant female: Report

Microbiology eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Microbiology eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in